Merck’s PAT sky rockets
Chirag Gothi / 13 May 2016
Merck has posted a standalone net profit that has jumped by 27.3 per cent at Rs 12.25 crore for the quarter ended March 31, 2016 as against Rs 9.62 crore in the corresponding quarter of the previous year.
Merck has posted a standalone net profit that has jumped by 27.3 per cent at Rs 12.25 crore for the quarter ended March 31, 2016 as against Rs 9.62 crore in the corresponding quarter of the previous year.
The company’s standalone revenue has grown marginally by 9.76 per cent at Rs 218.16 crore in Q1CY16. Its standalone operating profit (EBITDA) has grown by 33 per cent at Rs 17.22 crore along with operating profit margin expanding by 140 bps for the current quarter, i.e. at 7.90 per cent.
Pharmaceuticals segment has reported a growth of 23.33 per cent at Rs 169.88 crore, which contributes to around 78 per cent of the total revenue of the company. EBIT level of this segment has been reported at approximately 5.12 per cent margin. Chemical segment has reported a de-growth of 34.3 per cent; while EBIT level profit also has de-grown by 44.67 per cent at Rs 1.81 crore along with EBIT margin being contracted by 97 bps to 3.74 per cent in Q1CY16.
For the entire period of CY15, it has reported standalone net profit growth of 23.9 per cent at Rs 53.56 crore, while its revenue has grown by 8.3 per cent at Rs 939.50 crore. Its standalone operating profit (EBITDA) has grown by 41.7 per cent at Rs 83.44 crore along with operating profit margin expanding by 209 bps for the current quarter at 8.88 per cent.
Merck Limited is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments. The company operates through two segments: Pharmaceuticals and Chemicals. Its Pharmaceutical segment consists of Ethicals, which is used in the treatment of cardiovascular and metabolic diseases; consumer healthcare products; and vitamins-based formulations. The Pharmaceuticals segment has two business divisions: Merck Serono and Consumer Health. The company's Chemicals segment consists of bulk drugs and pigments.
On the valuation front, it is currently trading at 20.29 times, price to earnings (P/E) ratio per share of Rs 33.85 as on March 31, 2016. Currently stock is trading up by Rs 14 or 2.08 per cent at Rs 687 per share.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.